Meropenem/pralurbactam

美洛培南/普莱巴坦

Report date: 2026/02/25 20:02:36
NME

Base Information

Drug NameMeropenem/pralurbactam
Drug Alias Name美罗培南普莱巴坦
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBacterial penicillin-binding protein inhibitorsBeta Lactamase inhibitors
TargetsBacterial penicillin-binding proteinBeta Lactamase
Therapy Area/IndicationsHospital-acquired pneumoniaUrinary Tract InfectionsIntraabdominal Infections +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Meropenem
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQilu Antibiotics Pharmaceutical Co LtdQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHospital-acquired pneumoniaUrinary Tract InfectionsIntraabdominal Infections +[6] 
Inactive IndicationsInfections

Other Information

ATC CodeN/A
Related LinksN/A